drugset / Trial / NCT00912743

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

NCT00912743 ↗

Phase 2 Completed 33 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

This study is being carried out to see if the new drug, olaparib (AZD2281), can effectively and safely treat advanced large bowel cancer. The primary goal of this clinical trial is to determine whether olaparib will have a beneficial effect on the patient's cancer by causing a response and increasing the time it takes for the cancer to progress.

Timeline

Start
2009-05
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Olaparib Small molecule 400 mg Oral

Indications